Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors LMI070 - mRNA splicing modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT05111249 VIBRANT-HD (CLMI070C12203) Huntington's disease Phase 2 75 1. Reduction (%) of mHTT protein in cerebrospinal fluid (CSF) 2. Number of treatment emergent adverse events and serious adverse events Arm 1: Experimental; Branaplam 56 mg oral solution once weekly Arm 2: Experimental; Branaplam 112 mg oral solution once weekly Arm 3: Experimental; (C) Branaplam 154 mg oral solution once weekly, OR (X) Branaplam 84 mg oral solution once weekly OR (Y) Branaplam 28 mg oral solution once weekly Arm 4: Placebo; Matching placebo oral solution once weekly Participants with early manifest Huntington's Disease Target Patients Read-out Milestone(s) Publication 2025 TBD 72 Investor Relations | Q1 2022 Results References Abbreviations Hematology Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine

View entire presentation